Hansa Biopharma
Develops antibody-cleaving enzymes to treat rare diseases and enable organ transplants.
HNSA | ST
Overview
Corporate Details
- ISIN(s):
- SE0002148817 (+1 more)
- LEI:
- 549300LLEO25ZJJ3NT91
- Country:
- Sweden
- Address:
- Box 785, 220 07 Lund
- Website:
- https://www.hansabiopharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes innovative immunomodulating therapies for rare immunological diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology, which targets and inactivates immunoglobulin G (IgG) antibodies to inhibit harmful immune responses. This technology enables life-saving procedures, such as kidney transplantation for highly sensitized patients, and is being developed to treat a range of acute IgG-mediated autoimmune conditions. Key products include the enzyme imilfidase. The company's strategy involves drug discovery, development, commercialization, and partnerships to address significant unmet medical needs in transplantation and autoimmunity.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-31 14:37 |
Major Shareholding Notification
|
Swedish | 10.7 KB | ||
| 2025-10-31 12:00 |
Share Issue/Capital Change
Hansa Biopharma: Ökning av antalet aktier och röster
|
Swedish | 188.6 KB | ||
| 2025-10-31 12:00 |
Declaration of Voting Results & Voting Rights Announcements
Hansa Biopharma: Increase in number of shares and votes
|
English | 190.3 KB | ||
| 2025-10-30 07:00 |
Interim Report
|
Swedish | 1.7 MB | ||
| 2025-10-30 07:00 |
Interim Report
|
English | 2.1 MB | ||
| 2025-10-08 17:06 |
Major Shareholding Notification
|
Swedish | 10.8 KB | ||
| 2025-10-07 10:02 |
Major Shareholding Notification
|
Swedish | 10.9 KB | ||
| 2025-10-06 17:53 |
Major Shareholding Notification
|
Swedish | 10.0 KB | ||
| 2025-10-06 15:46 |
Major Shareholding Notification
|
Swedish | 10.1 KB | ||
| 2025-10-03 17:20 |
Major Shareholding Notification
|
Swedish | 12.4 KB | ||
| 2025-10-02 08:30 |
Share Issue/Capital Change
Hansa Biopharma publishes disclosure document for admission to trading of share…
|
English | 193.8 KB | ||
| 2025-10-02 08:30 |
Share Issue/Capital Change
Hansa Biopharma publicerar informationsdokument för upptagande till handel av a…
|
Swedish | 173.9 KB | ||
| 2025-10-02 00:15 |
Share Issue/Capital Change
Hansa Biopharma has carried out a directed share issue of 17 million shares, ra…
|
English | 231.2 KB | ||
| 2025-10-02 00:15 |
Share Issue/Capital Change
Hansa Biopharma har genomfört en riktad emission av 17 miljoner aktier, vilket …
|
Swedish | 226.1 KB | ||
| 2025-10-01 17:31 |
Share Issue/Capital Change
Hansa Biopharma avser genomföra en riktad nyemission om cirka 60 miljoner USD
|
Swedish | 212.4 KB |
Automate Your Workflow. Get a real-time feed of all Hansa Biopharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Hansa Biopharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Hansa Biopharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2021-05-07 | Soren Tulstrup | Other | Buy | 3,000 | 450,827.25 SEK |
| 2021-02-22 | Klaus Lykke Sindahl | Other | Buy | 592 | 100,403.20 SEK |
| 2021-01-19 | Petrus Lindh | Other | Buy | 300 | 55,710.00 SEK |
| 2020-09-07 | Klaus Lykke Sindahl | Other | Buy | 745 | 144,530.00 SEK |
| 2020-08-11 | Klaus Lykke Sindahl | Other | Buy | 300 | 76,800.00 SEK |
| 2020-03-06 | Klaus Lykke Sindahl | Other | Buy | 555 | 49,672.50 SEK |
Peer Companies
